 Cisplatin continuous-infusion intermediate-dose methotrexate treatment unresectable non-small cell carcinoma lung patients unresectable non-small cell carcinoma lung NSCCL cisplatin days daily bolus injection continuous infusion days intermediate-dose methotrexate days cycle PFM complete partial responses overall response rate significant difference response rates histologic subtype extent disease unresectable versus metastatic Median duration response months median survival patients months patients unresectable disease presentation resectable chemotherapy disease-free months Toxicity modest oral mucositis major adverse effect Clinically important neutropenia uncommon PFM active regimen NSCCL study neoadjuvant setting